Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 24 hours
Any time
Past hour
Past 7 days
Past 30 days
Best match
Most recent
22h
Exelixis Hold Rating: Navigating Legal Wins and Strategic Acquisitions Amid Uncertain Revenue Transition
Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...
22h
Exelixis Hold Rating: Patent Victory Secures Stability Amid Limited Growth Prospects
In a report released today, Peter Lawson from Barclays maintained a Hold rating on Exelixis (EXEL – Research Report), with a price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
One Direction singer dies
Gets minimum 28 years
US adults loneliness survey
Revives Fox News lawsuit
US Navy aircraft crashes
Exotic cat caught in suburb
Disney to debut new pass
To return to Atlanta in 2028
SpaceX sues CA regulators
Out of disaster loan money
Salton Sea conservation
Parents sue MA school
PA gun restrictions ruling
Felon voting rights upheld
Had benign cyst removed
$750M US chips grant
Ownership stake approved
To headline Atlanta rally
Cereal dyes protested
To invest in nuclear reactors
Must face US state lawsuits
Broadband data caps probe
'Click to cancel' finalized
$1.4B renovation deal OK'd
Ordered to pay $15 million
MI shooter drill settlement
New cervical cancer regimen
Abortion group sues Florida
To cut up to 2,500 jobs
Related topics
Exelixis
Merck & Co.
WELIREG
Pembrolizumab
Phases of clinical research
Feedback